Completed

14AWHGA Randomized, Double-blind, Placebo Controlled, Parallel Study Investigating the Effects of Activamp on Body Weight, Fat Loss, and Metabolic Markers in Healthy Overweight Participants

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Activamp

+ Placebo

Dietary SupplementOther
Who is being recruted

Body Weight

+ Signs and Symptoms

+ Pathological Conditions, Signs and Symptoms

From 21 to 55 Years
+27 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Placebo-ControlledPhase 2
Interventional
Study Start: September 2014
See protocol details

Summary

Principal SponsorKGK Science Inc.
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: September 1, 2014

Actual date on which the first participant was enrolled.

The purpose of this study is to determine the effects of Activamp, a product containing gynostemma pentaphyllum extract, on body weight, fat loss and metabolic markers in healthy overweight adults.

Official TitleA Randomized, Double-blind, Placebo Controlled, Parallel Study Investigating the Effects of Activamp on Body Weight, Fat Loss, and Metabolic Markers in Healthy Overweight Participants
Principal SponsorKGK Science Inc.
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

100 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 21 to 55 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Body WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Criteria

10 inclusion criteria required to participate
Healthy male or female 21-55 years of age

BMI of 25.0 kg/m2 to 29.9 kg/m2 (± 1.0kg/m2)

Must have negative urine pregnancy test at screening

Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result.

Show More Criteria

17 exclusion criteria prevent from participating
Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial

Subject who have experienced a greater than 10% variation in body weight in the past 3 months

History of, or current diagnosis of any major diseases of the cardiovascular, hepatic, renal, gastrointestinal, pulmonary or endocrine systems

History of surgery for weight loss (including gastric bypass or lapband)

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Capsules containing 225mg of Activamp (Gynostemma pentaphyllum extract), 1 capsule taken twice daily for 12 weeks

Group II

Placebo
1 capsule taken twice daily for 12 weeks

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

KGK Synergize Inc.

London, CanadaOpen KGK Synergize Inc. in Google Maps
CompletedOne Study Center